Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors

Phase 2

Completed

Conditions: Testicular Neoplasms
Germ Cell Tumors

Interventions: Drug: Cyclophosphamide
Drug: Cisplatin
Drug: Etoposide
Drug: Bleomycin
Drug: Carboplatin

First Posted Date: 2014-06-12

Last Posted Date: 2014-06-12

Lead Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Registration Number: NCT02161692

Locations: 🇮🇹
Istituto Nazionale dei Tumori, Milano, Italy

M6620 First in Human Study

Phase 1

Completed

Conditions: Advanced Solid Tumor

Interventions: Drug: M6620
Drug: Gemcitabine
Drug: Irinotecan
Drug: Cisplatin
Drug: Etoposide
Drug: Carboplatin

First Posted Date: 2014-06-06

Last Posted Date: 2020-04-01

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 200

Registration Number: NCT02157792

Locations: 🇺🇸
Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Long Island Jewish Medical Center - Monter Cancer Center, Lake Success, New York, United States

and more 27 locations

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

Phase 1

Active, not recruiting

Conditions: B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
Post-Transplant Lymphoproliferative Disorder
B-Cell Prolymphocytic Leukemia
High Grade B-Cell Lymphoma, Not Otherwise Specified
Recurrent Adult Burkitt Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Hairy Cell Leukemia
Recurrent Marginal Zone Lymphoma
Recurrent Small Lymphocytic Lymphoma
Recurrent Lymphoplasmacytic Lymphoma

Interventions: Biological: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
Drug: Bendamustine Hydrochloride
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Fludarabine Phosphate

First Posted Date: 2014-06-03

Last Posted Date: 2024-01-30

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 37

Registration Number: NCT02153580

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas

Phase 1

Completed

Conditions: Neuroblastoma
Lymphoma
High-risk Tumor

Interventions: Biological: CD133+ selected autologous stem cell infusion
Biological: IL-2
Biological: hu14.18K322A
Drug: Melphalan
Drug: Busulfan
Drug: Bendamustine
Biological: GM-CSF
Drug: Etoposide
Drug: Carboplatin
Device: Haploidentical natural killer cell infusion
Drug: Cytarabine
Biological: G-CSF
Device: CliniMACS
Drug: Etoposide phosphate

First Posted Date: 2014-05-06

Last Posted Date: 2017-12-22

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 8

Registration Number: NCT02130869

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma

Phase 1

Terminated

Conditions: Retinoblastoma
Advanced Intra-Ocular Retinoblastoma

Interventions: Drug: Melphalan
Drug: Carboplatin
Drug: Etoposide
Drug: Vincristine

First Posted Date: 2014-04-17

Last Posted Date: 2020-04-16

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 6

Registration Number: NCT02116959

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors

Phase 2

Active, not recruiting

Conditions: Atypical Teratoid Rhabdoid Tumor
Malignant Rhabdoid Tumor

Interventions: Drug: alisertib
Procedure: Surgical resection
Drug: methotrexate
Drug: cisplatin
Drug: carboplatin
Drug: cyclophosphamide
Drug: etoposide
Drug: topotecan
Drug: vincristine
Radiation: Radiation therapy

First Posted Date: 2014-04-15

Last Posted Date: 2024-10-31

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 125

Registration Number: NCT02114229

Locations: 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
Lucille Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States

and more 6 locations

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

Phase 3

Active, not recruiting

Conditions: Adult T Acute Lymphoblastic Leukemia
Ann Arbor Stage II Adult Lymphoblastic Lymphoma
Ann Arbor Stage II Childhood Lymphoblastic Lymphoma
Ann Arbor Stage III Adult Lymphoblastic Lymphoma
Ann Arbor Stage III Childhood Lymphoblastic Lymphoma
Ann Arbor Stage IV Adult Lymphoblastic Lymphoma
Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma
Childhood T Acute Lymphoblastic Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Bortezomib
Drug: Cytarabine
Drug: Daunorubicin
Drug: Daunorubicin Hydrochloride
Drug: Dexamethasone
Drug: Doxorubicin
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Drug: Hydrocortisone Sodium Succinate
Drug: Ifosfamide
Drug: Leucovorin Calcium
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Pegaspargase
Radiation: Radiation Therapy
Drug: Thioguanine
Drug: Vincristine
Drug: Vincristine Sulfate

First Posted Date: 2014-04-14

Last Posted Date: 2025-01-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 847

Registration Number: NCT02112916

Locations: 🇺🇸
Covenant Children's Hospital, Lubbock, Texas, United States
🇺🇸
UMC Cancer Center / UMC Health System, Lubbock, Texas, United States
🇦🇺
Monash Medical Center-Clayton Campus, Clayton, Victoria, Australia

and more 209 locations

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

Phase 3

Active, not recruiting

Conditions: Recurrent B Acute Lymphoblastic Leukemia

Interventions: Biological: Blinatumomab
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Drug: Asparaginase
Drug: Cytarabine
Drug: Dexamethasone
Drug: Etoposide
Drug: Leucovorin Calcium
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Pegaspargase
Drug: Mitoxantrone
Drug: Mitoxantrone Hydrochloride
Other: Pharmacological Study
Radiation: Radiation Therapy
Drug: Therapeutic Hydrocortisone
Drug: Thioguanine
Drug: Vincristine
Drug: Vincristine Sulfate

First Posted Date: 2014-04-02

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 669

Registration Number: NCT02101853

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
NYP/Weill Cornell Medical Center, New York, New York, United States
🇺🇸
State University of New York Upstate Medical University, Syracuse, New York, United States

and more 183 locations

Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients

Phase 2

Conditions: Sinonasal Tumors

Interventions: Drug: Cisplatin
Drug: Docetaxel
Drug: 5-fluorouracil
Drug: Etoposide
Drug: Adriamycin
Drug: Ifosfamide
Drug: Leucovorin
Radiation: Radiotherapy - Patients needing Elective Nodal Volume (ENI)
Radiation: Radiotherapy - Patients not needing ENI
Radiation: Radiotherapy - Patients needing curative neck irradiation

First Posted Date: 2014-03-28

Last Posted Date: 2023-03-13

Lead Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Target Recruit Count: 41

Registration Number: NCT02099175

Locations: 🇮🇹
Fondazione IRCCS Istituto Nazionale Tumori, Milano, MI, Italy
🇮🇹
Presidio Ospedaliero Spedali Civili di Brescia, Brescia, BS, Italy
🇮🇹
IRCCS Policlinico San Matteo, Pavia, PV, Italy

and more 2 locations

Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients

Phase 2

Conditions: Unresectable Sinonasal Tumors

Interventions: Drug: Cisplatin
Drug: Docetaxel
Drug: 5-fluorouracil
Drug: Etoposide
Drug: Adriamycin
Drug: Ifosfamide
Drug: Leucovorin
Radiation: Radiotherapy - Patients needing Elective Nodal Volume (ENI)
Radiation: Radiotherapy - Patients not needing ENI
Radiation: Radiotherapy - Patients needing curative neck irradiation

First Posted Date: 2014-03-28

Last Posted Date: 2023-03-13

Lead Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Target Recruit Count: 27

Registration Number: NCT02099188

Locations: 🇮🇹
Presidio Ospedaliero Spedali Civili di Brescia, Brescia, BS, Italy
🇮🇹
IRCCS Policlinico San Matteo, Pavia, PV, Italy
🇮🇹
A.O. Ospedale di Circolo e Fondazione Macchi, Varese, VA, Italy

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy